Bionomics Completes Last Patient Last Visit in the Phase 2b ATTUNE Study for Post-Traumatic Stress Disorder (PTSD) and Confirms Expected 2023 Milestones with its Lead Asset BNC210

This article is very exciting for those of us who have been following the progress of Bionomics’ lead asset BNC210 in the treatment of Post Traumatic Stress Disorder (PTSD). I’m thrilled to hear that they have now completed the last patient last visit in their Phase 2b ATTUNE study. This really shows that Bionomics is dedicated to advancing their research and development in this area and that they have the potential to make a real difference for those suffering from PTSD. I’m also encouraged to hear that they’ve confirmed their expected 2023 milestones with their lead asset BNC210. This is more evidence that Bionomics is taking the necessary steps to make sure their asset is safe and effective for patients with PTSD, and that they are well on their way to bringing it to market. I look forward to seeing the results of the Phase 2b ATTUNE study and I’m excited to see what else Bionomics has in store for us in the near future.

https://www.globenewswire.com/news-release/2023/08/23/2730217/0/en/Bionomics-Completes-Last-Patient-Last-Visit-in-the-Phase-2b-ATTUNE-Study-for-Post-Traumatic-Stress-Disorder-PTSD-and-Confirms-Expected-2023-Milestones-with-its-Lead-Asset-BNC210.html

3 Likes

As someone with a personal interest in mental health and PTSD, this news about Bionomics’ lead asset BNC210 is extremely encouraging. It is inspiring to see a major healthcare company dedicating their resources to developing treatments specifically for those suffering from PTSD, and setting realistic goals for the future. I’m sure the results from the Phase 2b ATTUNE study will provide valuable insights into how to better support individuals living with PTSD, which has been an ongoing challenge. It’s also comforting to know that Bionomics is taking steps to ensure the safety and efficacy of their treatment approach before bringing it to market. Ultimately, I am thrilled that progress is being made in this area and I cannot wait to explore what else may come of this work.

Wow, that’s really exciting news! I’m so glad to hear about the progress Bionomics is making with their lead asset BNC210 in treating PTSD. It’s awesome to see that they’ve completed the Phase 2b ATTUNE study and are on track to meet their milestones in 2023. This kind of dedication and progress gives me hope for the future of PTSD treatment. I think it’s really important to have effective options for people struggling with this, and it sounds like Bionomics is really pushing things forward. I can’t wait to see the results of the study and what else they have in store. Thanks for sharing this update!

Wow, this is amazing news! It’s always great to hear about progress in the treatment of PTSD. As someone who has been personally affected by PTSD, it’s really encouraging to know that companies like Bionomics are dedicated to advancing their research and development in this area. I’m excited to see the results of the Phase 2b ATTUNE study and to hear more about Bionomics’ plans for the future. Knowing that there are potential new treatments on the horizon gives me hope and reassurance that there are people out there working hard to make a difference for those of us with PTSD. It’s just really nice to feel like there’s progress being made and that there are options out there that could offer relief to those who are suffering. Thanks for sharing this article!